We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cytodyn Inc (CYDY) NPV

Sell:$0.33 Buy:$0.33 Change: $0.0188 (5.97%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $0.0188 (5.97%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $0.0188 (5.97%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CytoDyn Inc. is a biotechnology company that is focused on developing treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The Company also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The Company is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).

Contact details

1111 Main St Ste 660
United States
+1 (360) 9808524

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$226.27 million
Shares in issue:
718.32 million
Off Exchange
United States
US dollar

Key personnel

  • Tanya Urbach
    Chairman of the Board
  • Antonio Migliarese
    Interim President, Chief Financial Officer, Vice President, Controller, Treasurer
  • Michael Mulholland
    Senior Vice President - Finance
  • Nitya Ray
    Chief Technology Officer
  • Mahboob Rahman
    Chief Scientific Officer
  • Arian Colachis
    Vice President, General Counsel, Secretary
  • Scott Kelly
    Chief Medical Officer, Head of Business Development, Director
  • Seenu Srinivasan
    Executive Director - CMC Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.